CN112076200A - Application of hederagenin polyethylene glycol derivative - Google Patents

Abstract

The invention discloses an application of hederagenin polyethylene glycol derivatives. In particular, the hederagenin polyethylene glycol derivative provided by the invention is applied to preparing a tumor drug resistance reversal agent, and the hederagenin polyethylene glycol derivative with a novel structure type provided by the invention has improved water solubility and excellent tumor drug resistance reversal activity. The hederagenin polyethylene glycol derivative and the medicinal carrier are used for treating diseases or symptoms such as oral epithelial cancer, gastric cancer, lung cancer, cervical cancer, breast cancer or colon cancer and the like by being combined with clinical common antitumor medicaments. The hederagenin polyethylene glycol derivative and the application of the medical acceptable salt thereof are used for preparing tumor drug resistance reversal agents and/or medicinal carriers for treating mammals, preferably human diseases or symptoms.

Description

Application of hederagenin polyethylene glycol derivative

Technical Field

The invention relates to the field of organic synthesis and pharmaceutical chemistry, in particular to application of hederagenin polyethylene glycol derivatives with novel structures in preparation of tumor drug resistance reversal agents.

Technical Field

The incidence of tumors is rising year by year, and according to statistics, the number of cancer deaths worldwide in 2018 reaches 960 ten thousand. Multidrug resistance (MDR) is one of the major causes of tumor chemotherapy failure. Therefore, the development of novel tumor resistance reversal agents is a key focus of attention in the field of medicinal chemistry. Natural products such as ursolic acid, glycyrrhetinic acid and the like and derivatives thereof have been proved to have MDR reversal activity, so the natural products become one of the important sources of the tumor drug resistance reversal agent.

Hederagenin (H) is derived from Hederagenin (Hederagenin, H) of Hedera of Araliaceae, and is an oleanane-type pentacyclic triterpene compound. The preliminary study of the subject group finds that the hederagenin derivative H6 has certain tumor drug resistance reversal activity in vivo and in vitro, and the action mechanism is preliminarily clarified, so that the hederagenin derivative H6 is expected to be a new drug candidate compound for coping with clinical tumor drug resistance (see Yang YT, Guan DK, Lei L, et al. H6, a novel chemotherapy derivative, variants multidrug resistance in vitro and in vivo [ J ]. drainage & Applied Pharmacology,2018,341: 98-105). However, H6 has low solubility in water and needs to be formulated into liposomes for in vivo administration, which limits its application to some extent. Therefore, further improvement of water solubility and drug-forming property of H6 is an important point in future work.

Disclosure of Invention

The invention aims to provide application of hederagenin polyethylene glycol derivatives in preparation of drugs for tumor drug resistance reversal agents. The invention aims to solve the technical problems of searching a compound which has novel structure type, improved water solubility and excellent tumor drug resistance reversal activity, and further providing a pharmaceutical composition for treating oral epithelial cancer, gastric cancer, lung cancer, cervical cancer, breast cancer, colon cancer and the like by combining with a clinical common antitumor drug.

In order to solve the technical problems, the invention provides the following technical scheme:

the invention relates to an application of hederagenin polyethylene glycol derivatives shown in a general formula I and medically acceptable salts thereof in preparing tumor drug resistance reversal agents, and the compounds provided by the invention are compounds with novel structural types,

wherein the content of the first and second substances,

general formula I: r₁Represents R₂、R₂XR₂；

R₂Represents a non-substituted linear or branched alkyl group of 1 to 3 carbons;

x represents S, O, S-S;

n is 2 to 13, and n is a natural number.

Preferably, the compounds and their pharmaceutically acceptable salts, wherein,

general formula I: r₁Represents R₂、R₂XR₂；

R₂Represents a non-substituted linear or branched alkyl group of 1 to 3 carbons;

x represents S, O, S-S;

n＝2、3、4、9、13。

preferably, some of the compounds of the present invention are:

general formula I:

4- (23-oxoolean-12-en-28-oic acid benzyl ester and [3,2-b ] pyrazine) -4-oxo-butyric acid tetraethylene glycol ester;

1 ' - (23-oxoolean-12-en-28-oic acid benzyl ester-23-oxo [3,2-b ] pyrazine) -1 ' -propionyl-3, 3 ' -dithiopropionic acid triethylene glycol ester;

1 ' - (23-oxyolean-12-en-28-oic acid benzyl ester and [3,2-b ] pyrazine) -1 ' -acetyl-2, 2 ' -oxoacetic acid polyethylene glycol (600) ester;

1 ' - (23-oxyolean-12-en-28-oic acid benzyl ester and [3,2-b ] pyrazine) -1 ' -acetyl-2, 2 ' -thioacetic acid polyethylene glycol (400) ester;

1 ' - (23-oxyolean-12-en-28-oic acid benzyl ester and [3,2-b ] pyrazine) -1 ' -butyryl-4, 4 ' -dithio-butyric acid diethylene glycol ester.

The preparation route of the hederagenin polyethylene glycol derivative provided by the invention is as follows:

the hederagenin polyethylene glycol derivative with the general formula I is synthesized and prepared according to the following method:

a. taking hederagenin as a raw material, and protecting carboxyl by benzyl bromide in the presence of inorganic base;

b. protecting the hydroxyl at the 23-position by using tert-butyldimethylsilyl chloride;

c. the intermediate product protected by TBS is oxidized by pyridine chlorochromate to obtain 3-site hydroxyl;

d. reacting with ethylenediamine under the catalysis of sulfur;

e. under the acidic condition, removing the 23-bit protecting group;

f. under the catalysis of DMAP and EDCI, reacting with connecting chains such as succinic anhydride, 3 '-dithiodipropionic acid, diglycolic anhydride, thiodiglycolic anhydride, 4' -dithiodibutyric acid and the like;

g. reacting with polyethylene glycol under the catalysis of DMAP and EDCI to obtain a crude product;

h. and purifying the crude product by using a dialysis method and a column chromatography method in sequence to obtain the target compound.

The hederagenin polyethylene glycol derivative provided by the invention is applied to preparation of tumor drug resistance reversal agents, and the hederagenin polyethylene glycol derivative with a novel structure type provided by the invention has improved water solubility and excellent tumor drug resistance reversal activity.

The hederagenin polyethylene glycol derivative and the optical isomer of the compound or the pharmaceutically acceptable solvate thereof.

The effective amount of the compound of the general formula I or the salt thereof and the pharmaceutically acceptable carrier are used for treating diseases or symptoms such as oral epithelial cancer, gastric cancer, lung cancer, cervical cancer, breast cancer or colon cancer and the like by combining with clinical common antitumor drugs.

The hederagenin polyethylene glycol derivative with the general formula I and the application of the medical acceptable salt thereof are used for preparing tumor drug resistance reversal agents and/or medicinal carriers for treating mammals, preferably human diseases or symptoms.

Detailed Description

The invention is characterized in that the hederagenin polyethylene glycol derivative with the general formula I and the medically acceptable salt thereof have direct anti-tumor activity disappearance and good tumor drug resistance reversion effect compared with the hederagenin; the further innovation lies in that the hederagenin polyethylene glycol derivative and the medically acceptable salt thereof with the general formula I have improved water solubility and improved tumor drug resistance reversal activity compared with the hederagenin derivative H6, and have already been made into drug properties.

The present invention will be described in further detail below by way of examples, but the present invention is not limited to only the following examples.

Example 14 benzyl [3,2-b ] olean-12-en-28-oate]Pyrazine) -4-oxo-butyric acid tetraethylene glycol ester (H6-D-PEG)₂₀₀) Synthesis and characterization of

Dissolving compound hederagenin (472.0mg, 1.0mmol) in N, N-dimethylformamide (15.0mL), adding potassium carbonate (300.0mg, 2.1mmol) and benzyl bromide (0.2mL, 1.3mmol), and stirring at 50 deg.C for 6-10 h. Diluting the reaction solution with ethyl acetate (25.0mL), washing with water for three times, washing with saturated salt water for two times, drying with anhydrous sodium sulfate, filtering, evaporating under reduced pressure to remove solvent, and performing silica gel column chromatography (V)_{Petroleum ether}:V_{Ethyl acetate}10:1-5:1) to give a white solid (470.0mg, 83.0%).

The above compound (460.0mg, 0.8mmol) was dissolved in 20.0mL of dichloromethane, 4-dimethylaminopyridine (122.0mg, 1.0mmol) and tert-butyldimethylsilyl chloride (360.0mg, 2.4mmol) were added, and the mixture was stirred at room temperature for 4-8 h. The dichloromethane was evaporated, diluted with ethyl acetate (20.0mL), washed acidic with 5% HCl, washed neutral with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and column chromatographed (V)_{Petroleum ether}:V_{Ethyl acetate}30:1-15:1) to obtain white solid(383.0mg，70.0％)。

The above-mentioned compound (380.0mg, 0.6mmol) was dissolved in 15.0mL of dichloromethane, and fresh pyridinium chlorochromate (300.0mg, 1.3mmol) was added thereto and stirred at room temperature for 6 to 10 hours. Evaporating to remove dichloromethane, diluting with ethyl acetate (20.0mL), washing with water, washing with saturated salt water to neutral, drying with anhydrous sodium sulfate, filtering, concentrating, and performing column chromatography (V)_{Petroleum ether}:V_{Ethyl acetate}35:1-20:1) to give a white solid (319.0mg, 84.0%).

Dissolving the above compound (500.0mg, 0.7mmol) in morpholine (25.0mL), adding sulfur (0.3g, 10.0mmol) and ethylenediamine (0.3g, 4.5mmol), refluxing for 6-10h, diluting with ethyl acetate (30.0mL), washing with water three times, washing with saturated salt water twice, drying over anhydrous sodium sulfate, filtering, concentrating, and performing column chromatography (V)_{Petroleum ether}:V_{Ethyl acetate}30:1-10:1) to give a white solid (357.0mg, 68.0%).

Dissolving the above product (300.0mg, 0.4mmol) in acetone (20.0mL), adding 10% HCl (2.0mL), stirring at room temperature for 3-5h, diluting with ethyl acetate, washing with water to neutrality, washing with saturated salt water, drying with anhydrous sodium sulfate, filtering, concentrating, and performing column chromatography (V)_{Petroleum ether}:V_{Ethyl acetate}5:1-8:1) to give H6(225.0mg, 89.0%) as a white solid.

The above compound H6(443.0mg, 0.7mmol) was dissolved in anhydrous dichloromethane (25.0mL), and the catalyst DMAP (453.4mg, 3.7mmol) and succinic anhydride (742.8mg, 7.4mmol) were added to react at room temperature for 2H. After the reaction is finished, dichloromethane is added for dilution, the organic layer is washed once by 5 percent HCl solution and washed twice by deionized water and saturated sodium chloride solution respectively in turn, dried by anhydrous sodium sulfate, filtered, concentrated and chromatographed by silica gel column (V)_Chloroform：V_Methanol50:1-20:1) to give H6-D as a white solid (466.0mg, 90.2%).

Tetraethylene glycol (180.0. mu.L, 1.1mmol) was dissolved in anhydrous dichloromethane (6.0mL), H6-D (80.0mg, 0.1mmol), DMAP (133.2mg, 1.1mmol) as a catalyst, EDCI (132.0mg, 0.7mmol) were added, and the reaction was stirred at room temperature for about 10 hours. After the reaction is finished, the solvent is removed by reduced pressure distillation, dissolved by methanol, dialyzed by deionized water for 3 days, and subjected to silica gel column chromatography (V)_{Methylene dichloride}:V_Methanol150:1) to give H6-D-PEG as a pale yellow oily liquid₂₀₀(58.0mg，58.0％)。¹H NMR(400MHz,CDCl₃)8.41(d,J＝2.4Hz,1H,H-pyrazine),8.29(d,J＝2.5Hz,1H,H-pyrazine),7.36-7.30(m,5H,5×H-Ar),5.37(s,1H,H-12),5.13-5.04(m,2H,CH₂Ar),4.32(d,J＝10.5Hz,1H,H-23a),4.27(d,J＝10.5Hz,1H,H-23b),4.21-4.16(m,2H,CH₂O PEG group),3.74-3.59(m,14H,CH₂O PEG group),2.99-2.93(m,2H,H-1a,H-18),2.54(d,J＝16.4Hz,1H,H-1b),2.49-2.34(m,4H,2×CH₂),1.27(s,3H,CH₃),1.19(s,3H,CH₃),0.94(s,3H,CH₃),0.91(s,3H,CH₃),0.88(s,3H,CH₃),0.69(s,3H,CH₃).

Example 21' - (23-Oxyhneta-12-en-28-oic acid benzyl ester [3,2-b ]]Pyrazine) -1 '-propionyl-3, 3' -dithiopropionic acid triethylene glycol ester (H6-S-PEG₁₅₀) Synthesis and characterization of

H6(100.0mg, 0.2mmol) was dissolved in dry dichloromethane (8.0mL), the catalysts DMAP (102.3mg, 0.8mmol), EDCI (160.6mg, 0.8mmol) and 3, 3' -dithiodipropionic acid (352.3mg, 1.7mmol) were added and the reaction was refluxed at 40 ℃ for 7H. After the reaction was completed, dichloromethane was added for dilution, and the organic layer was washed once with 5% HCl solution, twice with deionized water and twice with saturated sodium chloride solution, respectively, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain H6-S (121.9mg, 92.2%) as a white solid.

Triethylene glycol (131.7. mu.L, 1.1mmol) was dissolved in anhydrous dichloromethane (8.0mL), H6-S (88.0mg, 0.1mmol), DMAP (129.4mg, 1.1mmol) as a catalyst, EDCI (128.3mg, 0.7mmol) were added, and the reaction was stirred at room temperature for about 10H. After the reaction is finished, the solvent is removed by reduced pressure distillation, dissolved by methanol, dialyzed by deionized water for 3 days, and subjected to silica gel column chromatography (V)_{Methylene dichloride}:V_Methanol180:1) to give H6-S-PEG as a pale yellow oily liquid₁₅₀(52.0mg，48.7％)。¹H NMR(400MHz,CDCl₃)8.42(d,J＝2.5Hz,1H,H-pyrazine),8.30(d,J＝2.5Hz,1H,H-pyrazine),7.36-7.29(m,5H,5×H-Ar),5.37(s,1H,H-12),5.13-5.04(m,2H,CH₂Ar),4.35(d,J＝10.5Hz,1H,H-23a),4.28(d,J＝10.5Hz,1H,H-23b),4.27-4.25(m,2H,CH₂O PEG group),3.74-3.60(m,10H,CH₂O PEG group),2.99-2.93(m,2H,H-1a,H-18),2.85(t,J＝7.3Hz,2H,CH₂),2.71(t,J＝6.9Hz,2H,CH₂),2.70-2.65(m,2H,CH₂),2.53(s,1H,H-1b),2.52-2.49(m,2H,CH₂),1.28(s,3H,CH₃),1.18(s,3H,CH₃),0.94(s,3H,CH₃),0.91(s,3H,CH₃),0.88(s,3H,CH₃),0.69(s,3H,CH₃).

Example 31' - (23-Oxyhneta-12-en-28-oic acid benzyl ester [3,2-b ]]Pyrazine) -1 '-acetyl-2, 2' -oxoacetic acid polyethylene glycol (600) ester (H6-E-PEG₆₀₀) Synthesis and characterization of

H6(70.0mg, 0.1mmol) was dissolved in dry dichloromethane (8.0mL), and the catalyst DMAP (71.6mg, 0.6mmol) and diglycolic anhydride (68.0mg, 0.6mmol) were added and reacted at room temperature for 0.5H. After the reaction was completed, dichloromethane was added for dilution, and the organic layer was washed once with 10% HCl solution, twice with deionized water and twice with saturated sodium chloride solution, respectively, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain H6-E (78.0mg, 93.3%) as a white solid.

Polyethylene glycol 600 (543.4. mu.L, 1.2mmol) was dissolved in anhydrous dichloromethane (8.0mL), H6-E (82.0mg, 0.1mmol), DMAP (133.5mg, 1.1mmol) as a catalyst, EDCI (132.3mg, 0.7mmol) were added, and the reaction was stirred at room temperature for about 10H. After the reaction is finished, the solvent is removed by reduced pressure distillation, dissolved by methanol, dialyzed by deionized water for 3 days, and subjected to silica gel column chromatography (V)_{Methylene dichloride}:V_Methanol75:1) to give H6-E-PEG as a pale yellow oily liquid₆₀₀(61.0mg，40.9％)。¹H NMR(400MHz,CDCl₃)8.42(s,1H,H-pyrazine),8.30(s,1H,H-pyrazine),7.37-7.30(m,5H,5×H-Ar),5.37(s,1H,H-12),5.13-5.04(m,2H,CH₂Ar),4.38(d,J＝10.5Hz,1H,H-23a),4.33(d,J＝10.5Hz,1H,H-23b),4.29-4.25(m,2H,CH₂O PEG group),4.05-3.90(m,4H,2×CH₂),3.74-3.59(m,50H,CH₂O PEG group),3.03-2.91(m,2H,H-1a,H-18),2.46(d,J＝16.6Hz,1H,H-1b),1.29(s,3H,CH₃),1.18(s,3H,CH₃),0.94(s,3H,CH₃),0.91(s,3H,CH₃),0.88(s,3H,CH₃),0.69(s,3H,CH₃).

Example 41' - (23-Oxyhneta-12-en-28-oic acid benzyl ester and [3,2-b ]]Pyrazine) -1 '-acetyl-2, 2' -Thioacetic acid polyethylene glycol (400) ester (H6-S1-PEG₄₀₀) Synthesis and characterization of

H6(100.0mg, 0.2mmol) was dissolved in anhydrous dichloromethane (8.0mL), and the catalyst DMAP (102.3mg, 0.8mmol) and thiodiglycolic anhydride (110.7mg, 0.8mmol) were added and reacted at room temperature for 10 min. After the reaction, dichloromethane was added to dilute the reaction solution, and the organic layer was washed with 10% HCl solution once, and washed with deionized water and saturated sodium chloride solution twice, respectively, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain H6-S1(115.9mg, 95.0%) as a white solid.

Polyethylene glycol 400 (862.9. mu.L, 2.7mmol) was dissolved in anhydrous dichloromethane (8.0mL), H6-S1(200mg, 0.3mmol), DMAP (318.7mg, 2.6mmol) as a catalyst, EDCI (315.8mg, 1.6mmol) were added, and the reaction was stirred at room temperature for about 10H. After the reaction is finished, the solvent is removed by reduced pressure distillation, dissolved by methanol, dialyzed by deionized water for 3 days, and subjected to silica gel column chromatography (V)_{Methylene dichloride}:V_Methanol120:1) to give H6-S1-PEG as a pale yellow oily liquid₄₀₀(146.9mg，48.2％)。¹H NMR(400MHz,CDCl₃)8.43(d,J＝2.3Hz,1H,H-pyrazine),8.30(d,J＝2.4Hz,1H,H-pyrazine),7.37-7.29(m,5H,5×H-Ar),5.38(s,1H,H-12),5.13-5.04(m,2H,CH₂Ar),4.41(d,J＝10.5Hz,1H,H-23a),4.32(d,J＝10.5Hz,1H,H-23b),4.28-4.21(m,2H,CH₂O PEG group),3.74-3.64(m,32H,CH₂O PEG group),3.23-3.14(m,2H,CH₂),3.14-3.00(m,2H,CH₂),2.99-2.93(m,2H,H-1a,H-18),2.58(d,J＝16.6Hz,1H,H-1b),1.28(s,3H,CH₃),1.17(s,3H,CH₃),0.94(s,3H,CH₃),0.91(s,3H,CH₃),0.89(s,3H,CH₃),0.69(s,3H,CH₃).

Example 51' - (23-Oxyhneta-12-en-28-oic acid benzyl ester [3,2-b ]]Pyrazine) -1 '-butyryl-4, 4' -dithiobutanoic acid diethylene glycol ester (H6-S4-PEG₁₀₀) Synthesis and characterization of

H6(100.0mg, 0.2mmol) was dissolved in dry dichloromethane (8.0mL), the catalysts DMAP (102.3mg, 0.8mmol), EDCI (160.6mg, 0.8mmol) and 4, 4' -dithiodibutanoic acid (199.6mg, 0.8mmol) were added and the reaction was refluxed at 40 ℃ for 0.5H. After the reaction, dichloromethane was added to dilute the reaction solution, and the organic layer was washed with 5% HCl solution once, deionized water and saturated sodium chloride solution twice, respectively, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain H6-S4 as a white solid (125.8mg, 92.0%).

Diethylene glycol (144.7. mu.L, 1.8mmol) was dissolved in anhydrous dichloromethane (8.0mL), H6-S4(150mg, 0.2mmol), DMAP (213.2mg, 1.7mmol) as a catalyst, EDCI (211.3mg, 1.1mmol) were added, and the reaction was stirred at room temperature for about 10H. After the reaction is finished, the solvent is removed by reduced pressure distillation, dissolved by methanol, dialyzed by deionized water for 3 days, and subjected to silica gel column chromatography (V)_{Methylene dichloride}:V_Methanol200:1) to obtain light yellow oily liquid H6-S4-PEG₁₀₀(96.4mg，58.0％)。¹HNMR(400MHz,CDCl₃)8.42(d,J＝2.4Hz,1H,H-pyrazine),8.30(d,J＝2.4Hz,1H,H-pyrazine),7.37-7.29(m,5H,5×H-Ar),5.38(s,1H,H-12),5.13-5.03(m,2H,CH₂Ar),4.28(s,2H,H-23),4.27-4.23(m,2H,CH₂O PEG group),3.78-3.59(m,6H,CH₂O PEG group),2.98(m,2H,H-1a,H-18),2.66(t,J＝7.1Hz,2H,CH₂),2.51(d,J＝10.3Hz,1H,H-1b),2.46(t,J＝7.6Hz,4H,2×CH₂),2.28-2.14(m,2H,CH₂),2.03-1.95(m,4H,2×CH₂),1.28(s,3H,CH₃),0.94(s,3H,CH₃),0.91(s,3H,CH₃),0.88(s,3H,CH₃),0.69(s,3H,CH₃).

The following are the pharmacological tests and data for some of the compounds of the invention.

1 experimental method: examples 1-5 detection of the survival Rate of the antitumor drug paclitaxel in KBV resistant Strain cells

KBV cells in logarithmic phase are digested with 0.25% pancreatin to prepare single cell suspension with certain concentration. Based on the difference in cell growth rate, the cells were seeded at 4000 wells in a 96-well plate, and 100. mu.L of cell suspension was added to each well. After 24h, complete medium was added at various concentrations of compound and 100nM of paclitaxel and corresponding solvent control. mu.L of DMSO (final DMSO concentration < 0.1%) was added to each well, 3 wells were placed in each group, incubation was continued at 37 ℃ for 72h, and the supernatant was discarded. Add 100. mu.L per well of MTT 0.5mg/mLAnd (3) completely culturing the culture medium for 4 hours, removing the supernatant, adding 150 mu L of LDMSO into each well to dissolve MTT formazan precipitate, uniformly mixing the mixture by using a micro oscillator, and measuring an optical density value (OD) by using an enzyme-labeling instrument under the conditions of a reference wavelength of 450nm and a detection wavelength of 570 nm. Using tumor cells treated by solvent control as a control group, and calculating the survival rate of different tumor cells under the action of each compound by using the following formula; tumor cells treated by solvent control are used as a control group, the inhibition rate of the compound on the tumor cells is calculated by the following formula, and the IC is calculated according to the middle effect equation₅₀。

Cell survival rate (%). The average OD value of the administered group/the average OD value of the control group X100%

IC₅₀(control group mean OD value-administration group mean OD value)/control group mean OD value. times.100%

2, experimental results:

examples 1-5 cell viability when administered alone and in combination is shown in Table 1.

TABLE 1 cell viability of examples 1-5 when administered alone and in combination

Examples 1-5 viability assay of anti-tumor drug paclitaxel in KBV resistant strain cells.

The survival rate evaluation results of KBV drug-resistant strain cells of the derivatives show that the examples 1-4 have better tumor drug resistance reversal activity, wherein the activity is the best example 1. Research results show that the synthesized partial compound can obviously increase the antiproliferative activity of the paclitaxel, and the action intensity is superior to verapamil with equal dosage and is superior to H6.

The following are solubility determination tests and data for some of the compounds of the present invention.

1 experimental method: solubility tests were performed on examples 1-5

The excess compound was added to 4mL of deionized water, respectively, and the suspension was placed in a constant temperature shaker, shaken at 37 ℃ for 24 hours, and then centrifuged at 14,000r/min in a centrifuge for 5 minutes. The supernatant was filtered through a 0.45 μm microporous membrane, diluted appropriately, and the concentration of the compound was measured by UV-visible spectrophotometry to obtain the solubility of the compound in water.

2, experimental results:

examples 1-5 solubility data are shown in table 2.

TABLE 2 examples 1-5 solubility

The solubility measurement results of examples 1-5 show that the water solubility of the hederagenin polyethylene glycol derivative is remarkably improved compared with that of the lead compound H6, and particularly, the water solubility of example 3 is improved by about 1000 times.

Pharmacological tests and solubility determination tests prove that the hederagenin polyethylene glycol derivative provided by the invention improves water solubility while maintaining or improving tumor drug resistance reversal activity, can be used for preparing an MDR reversal agent, is used together with common antitumor drugs, and exerts good antitumor activity.

The experiments show that the polyethylene glycol modification method is introduced into the structural modification of H6, and the polyethylene glycol is connected to H6 through a connecting chain, so that the hederagenin polyethylene glycol derivative with the novel structure and improved tumor drug resistance reversion activity and remarkably improved water solubility is obtained, namely the hederagenin polyethylene glycol derivative with the general formula I and the structure modification of the pharmaceutically acceptable salt thereof are successful, the direct anti-tumor activity disappears compared with the hederagenin, the water solubility is remarkably improved on the premise that the hederagenin polyethylene glycol derivative with the general formula I and the pharmaceutically acceptable salt thereof have good tumor drug resistance reversion effect and the activity is better than that of H6, and the hederagenin polyethylene glycol derivative with the general formula I and the pharmaceutically acceptable salt thereof have the drug properties.

Although the preferred embodiments of the present invention have been described in detail, the present invention is not limited to the details of the embodiments, and various equivalent modifications can be made within the technical spirit of the present invention, and the scope of the present invention is also within the scope of the present invention. It should be noted that the various features described in the above embodiments may be combined in any suitable manner without departing from the scope of the invention. The invention is not described in detail in order to avoid unnecessary repetition. In addition, any combination of the various embodiments of the present invention is also possible, and the same should be considered as the disclosure of the present invention as long as it does not depart from the spirit of the present invention.

Claims (3)

1. Application of hederagenin polyethylene glycol derivatives shown in general formula I and medically acceptable salts thereof in preparing tumor drug resistance reversal agents,

wherein the content of the first and second substances,

R₁represents R₂、R₂XR₂；

R₂Represents a non-substituted linear or branched alkyl group of 1 to 3 carbons;

x represents S, O, S-S;

n is 2 to 13, and n is a natural number.

2. The use according to claim 1, characterized in that the hederagenin polyethylene glycol derivative represented by the general formula I and the pharmaceutically acceptable salt thereof,

R₁represents R₂、R₂XR₂；

R₂Represents a non-substituted linear or branched alkyl group of 1 to 3 carbons;

x represents S, O, S-S;

n＝2、3、4、9、13。

3. the use according to claim 1, characterized in that the hederagenin polyethylene glycol derivative represented by the general formula I and the pharmaceutically acceptable salt thereof are as follows:

4- (23-oxoolean-12-en-28-oic acid benzyl ester and [3,2-b ] pyrazine) -4-oxo-butyric acid tetraethylene glycol ester;

1 ' - (23-oxoolean-12-en-28-oic acid benzyl ester-23-oxo [3,2-b ] pyrazine) -1 ' -propionyl-3, 3 ' -dithiopropionic acid triethylene glycol ester;

1 ' - (23-oxyolean-12-en-28-oic acid benzyl ester and [3,2-b ] pyrazine) -1 ' -acetyl-2, 2 ' -oxoacetic acid polyethylene glycol (600) ester;

1 ' - (23-oxyolean-12-en-28-oic acid benzyl ester and [3,2-b ] pyrazine) -1 ' -acetyl-2, 2 ' -thioacetic acid polyethylene glycol (400) ester;

1 ' - (23-oxyolean-12-en-28-oic acid benzyl ester and [3,2-b ] pyrazine) -1 ' -butyryl-4, 4 ' -dithio-butyric acid diethylene glycol ester.